Background. Mucormycosis is a rare and invasive fungal infection, affecting almost exclusively immunocompromised individuals. Immunosuppressive effects of corticosteroids which are widely prescribed in COVID-19 patients might be a predisposing factor for opportunistic infections even though the other factors should also be considered. Case Presentation. A middle-aged man without any significant past medical history was admitted to the hospital due to a severe COVID-19 infection. He received a high dose of corticosteroids as a part of the treatment. Five days after discharge, he presents with a headache and fever. Eventually, orbital mucormycosis was diagnosed for him and he was treated with antifungal medications. Conclusion. Opportunistic infections should be considered during the current pandemic of COVID-19, during which corticosteroids are widely prescribed.

1. Background
Mucormycosis is a rare, potentially fatal infection caused by fungi from the order Mucorales. [1, 2]. It has various clinical presentations and predominantly affects immunocompromised patients, especially those with diabetes, renal failure, hematological malignancies, and transplant recipients [3, 4]. Because of the high mortality and morbidity rate, prompt diagnosis and intervention are essential [5]. In this case report, we present a male patient with no underlying disease who presented with orbital mucormycosis following hospitalization due to coronavirus disease 2019 (COVID-19) infection. We also aimed to find out the possible association between mucormycosis, COVID-19 infection, and/or medication used to treat them.

2. Case Presentation
A 51-year-old man without past medical or social history presented with fever and cough, followed by dyspnea. He was referred to the Khalije Fars Hospital, Bushehr, and admitted there with the impression of COVID-19 in July 2020. The patient's temperature was 39.4°C, and his pulse was 84/minute. Bilateral fine crackles were auscultated on both lungs. Chest computerized tomography (CT) revealed a patchy ground-glass appearance in both lungs, in favor of
COVID-19 (Figure 1). The real-time reverse transcription-polymerase chain reaction (RT-PCR) test was positive for COVID-19.

Laboratory evaluation revealed leukopenia with white blood cell counts (WBC) of 2700 per/μL and lymphocyte count of 864/μL. Additionally, mild thrombocytopenia (platelet: 128000 per/μL) and elevated qualitative C-reactive protein (+3) were detected.

Based on a definite diagnosis of COVID-19, he received dexamethasone 4 mg intravenously (IV) per day along with ceftriaxone 1 gram IV for the prevention of bacterial superinfection. After 5 days of treatment (20 mg dexamethasone totally), the patient (Pt) was discharged with stable vital signs, without leukopenia (WBC: 7200/μL) or any other complications. Prednisolone 25 mg, daily, was prescribed for him.

Seven days after the hospital discharge (20 mg dexamethasone and 175 mg prednisolone so far), the patient presented with severe headache, but without any significant findings in his physical exam. The brain magnetic resonance imaging (MRI) was in favor of sinusitis (Figure 2). Hence, oral amoxicillin-clavulanate 625 milligram (mg) every 8 hours (Q8h) was prescribed.

However, his condition did not improve, and he developed right (Rt) side preorbital edema (Figure 3) and redness that eventually spread to the left (Lt) side, so he was referred to an ophthalmologist for better evaluation.

In his physical examination, tenderness over the sinuses and bilateral preorbital edema were found. The paranasal sinus (PNS) CT scan showed osteomeatal obliteration associated with opacification of bilateral maxillary, ethmoid, frontal, and the Rt sphenoid sinus, suggestive of sinusitis (Figure 4). At this stage, the consumption of oral prednisolone was stopped (in total, 20 mg dexamethasone, and 300 mg prednisolone).

Levofloxacin was prescribed for him with the dosage of 750 mg orally, daily along with artificial tear 1 drop every 4 hours and ciprofloxacin eye drops 1 drop every 8 hours, but his condition worsened; therefore, the patient was referred to an otorhinolaryngologist. The otorhinolaryngologist found a palate lesion in the patient’s mouth and took a biopsy from the palate lesion with suspicion of mucormycosis, but no evidence of mucormycosis was found in his pathology. After 5 days, the patient was transferred to Khalili hospital, Shiraz, which is the referral center of otorhinolaryngology and ophthalmology, for anterior orbitotomy due to abscess development. Because of the dangerous condition of the Rt side-eye and the possible disruption of the orbital bones and spread of the infection to the Rt eye, the Lt eye underwent anterior orbitotomy and a cloudy liquid discharge with necrosis and oily component that extended to the orbital wall bone was seen in surgery. The patient was discharged with levofloxacin (750 mg, orally, daily) for sinusitis and prednisolone with a daily dose of 50 mg orally due to suspicion of autoimmune disease.

Three days after his discharge, the patient’s condition did not improve, but also, he presented with reduced visual acuity of the Rt eye from 10/10 to 8/10; therefore, the patient has admitted again to Khalili hospital, and in a joint assessment by the ophthalmology and otorhinolaryngology experts, a functional endoscopic sinus surgery (Fess) along with another anterior orbitotomy was performed for the patient. During Fess, necrosis and pusy discharge were found in the paranasal sinuses, and samples from the orbital tissue, nasal cavity, and sinuses were obtained for pathological evaluation and sent to the laboratory of Khalili hospital, affiliated by Shiraz University of Medical Sciences.

Pathology evaluation of the paranasal sinus tissue showed heavy infiltration of acute and chronic inflammatory cells with an area of necrosis and hypha of the mucor fungus surrounded by polymorphonuclear leukocytes, which were in favor of mucormycosis (Figure 5).

The patient was evaluated for human immunodeficiency virus which was negative. Subsequently, antifungal therapy with Amphotericin B lipid complex (200 mg, IV, daily) was started for the patient. The patient was also transferred to Namazi hospital, a referral center affiliated with Shiraz University of Medical Sciences for continuing his antifungal therapy; this hospital has infectious disease specialists.

In Nemazi hospital, visual acuity was reduced to 1/10 and 4/10 in the Rt and Lt eye, respectively. The new PNS CT scan showed progression of the infection (Figure 6).

Therefore, his antifungal treatment regimen was adjusted to Caspofungin (80 mg, IV, daily) and Amphotericin B lipid complex (350 mg, IV, daily) which continued for about one month. Also, for reducing the chance of bacterial superimpose infection, piperacillin-tazobactam (4.5 gr, IV, Q12h) and teicoplanin (400 mg, IV, QD) were administered. During his treatment course, the patient developed hypokalemia, and increased blood urea nitrogen (BUN) and creatinine levels; therefore, Amphotericin dosage was adjusted to 200 mg, IV per day. Also, sixteen days after hospital admission, another Fess with Amphotericin irrigation was done for the patient. He was discharged after 59 days of hospitalization in Nemazi and Khalili hospitals after taking 15700 mg Amphotericin B lipid complex for 56 days, 2400 mg Caspofungin for 30 days, leading to favorable healing. At the time of discharge, the patient had better visual acuity in both eyes (6/10 in the Rt eye and 8/10 in the Lt eye), no orbital or preorbital edema, and tenderness.
COVID-19 was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. In the current context, with respect to the increase in the number of infected patients with COVID-19 as well as the emergence of new species, corticosteroids have been prescribed widely for not only in critically ill patients but also some of the mild to moderate ones regardless of the potential rare adverse complications. In this case report, we described a sinoorbital mucormycosis in an immunocompetent middle age man that was previously treated with high doses of corticosteroid for the prevention of lung fibrosis following COVID-19 infection. In spite of the difficulties of diagnosing the disease, it was successfully managed with medical and surgical interventions.

Corticosteroids have a strong anti-inflammatory effect and are considered to have a role in treating immunologic complications of COVID-19 infection like cytokine storm, lung inflammation, fever, and abnormal laboratory indices of inflammation [5–7]. Observational studies showed that corticosteroid treatment was linked with higher mortality rates and nosocomial infections for influenza and delayed virus clearance for SARS-CoV and MERS-CoV; however, there is limited data regarding SARS-CoV-2 [8]. Also, corticosteroids have been associated with an increased risk of superinfection including bacterial, mycobacterial, and fungal infections [9–12]. Furthermore, several studies have particularly warned about the foregoing adverse effects of corticosteroids in patients with the comorbid disease, but there is little evidence of serious infectious complications in

3. Discussion

COVID-19 was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. In the current context, with respect to the increase in the number of infected patients with COVID-19 as well as the emergence of new species, corticosteroids have been prescribed widely for not only in critically ill patients but also some of the mild to moderate ones regardless of the potential rare adverse complications. In this case report, we described a sinoorbital mucormycosis in an immunocompetent middle age man that was previously treated with high doses of corticosteroid for the prevention of lung fibrosis following COVID-19 infection. In spite of the difficulties of diagnosing the disease, it was successfully managed with medical and surgical interventions.

Corticosteroids have a strong anti-inflammatory effect and are considered to have a role in treating immunologic complications of COVID-19 infection like cytokine storm, lung inflammation, fever, and abnormal laboratory indices of inflammation [5–7]. Observational studies showed that corticosteroid treatment was linked with higher mortality rates and nosocomial infections for influenza and delayed virus clearance for SARS-CoV and MERS-CoV; however, there is limited data regarding SARS-CoV-2 [8]. Also, corticosteroids have been associated with an increased risk of superinfection including bacterial, mycobacterial, and fungal infections [9–12]. Furthermore, several studies have particularly warned about the foregoing adverse effects of corticosteroids in patients with the comorbid disease, but there is little evidence of serious infectious complications in

Figure 2: Axial T2-weighted images without contrast administration show (a) mucosal thickening and secretion in the right maxillary sinus and a retention cyst in the left maxillary sinus and (b) mucosal thickening and secretion in the right ethmoid sinus with a lesser degree in the left ethmoid sinus.

Figure 3: Rt side preorbital edema and redness.
immunocompetent patients without any comorbidities [13–15]. The aforementioned information did not mean to attribute this fungal infection to corticosteroid consumption accurately and purely or did not request corticosteroid elimination. It seeks to warn of the adverse and potentially fatal effects of steroids that may be overlooked because of their many benefits and also to give physicians a comprehensive overview of prescribing the drug.

Mucormycosis is a life-threatening fungal infection that primarily affects patients with immunosuppression [16]. In a study of 101 cases of mucormycosis reported by Lanternier et al., the median number of underlying medical conditions was 2 per patient [17]. Diabetes, hematological malignancies, transplantation, HIV infection, and systemic lupus erythematosus are examples of recognized conditions associated with mucormycosis [16, 18]. The fact that our patient lacked usual comorbidities was associated with a delayed diagnosis of the disease.

As indicated previously, treatment with corticosteroid causes immunosuppression in patients with COVID-19 infection; thus, mucormycosis should be considered as a potential infection affecting them. However, the role of SARS-CoV-2 infection on the cells of the innate immunity (macrophage and neutrophils) should be considered. Our review of the literature indicates that there have been reports of many cases of secondary cases of mucormycosis which is called COVID-19-Associated Mucormycosis (CAM). Those cases have orbital, rhinoorbital, gastrointestinal, and pulmonary involvement [12, 19–22]. In a
recent review, a significant percentage of patients with mucormycosis also had a bacterial or fungal coinfection [12]. In a study by Muthu et al., 2,568 cases of CAM are reported which most of them were also affected by diabetes mellitus [23]. Rudramurthy et al. also claimed that uncontrolled diabetes mellitus and inappropriate (high dose or not indicated) corticosteroid use are the major predisposing factors for this surge. Furthermore, a hyperglycaemic state leads to hyperferritinaemia and increased expression of the glucose-regulated protein (GRP-78) in endothelial cells that may help the entry of Mucorales into tissues [24]. The systematic review of literature reveals that there is a significant increase in mucormycosis due to COVID-19, in specific parts of the world, such as India. The reasons for this unprecedented increase remain unknown [25].

The patient was a healthy man that had received high doses of corticosteroids and broad-spectrum antibiotics due to COVID-19. The sign of orbital infection emerged 12 days after the first dose of corticosteroids. Given the lack of any underlying and previous disease or any proven coinfection (e.g., positive urine or blood culture) that usually leads to opportunistic fungal infections such as mucormycotic, we attributed the current infection to the condition called CAM as well as high dose and long duration of corticosteroid administration and its effects on systemic immunosuppression. However, the role of other factors such as iron and zinc metabolism, immunomodulatory effects of COVID-19, endothelial dysfunction which is met in COVID-19 infection, and overexpression of GRP78 should be considered. Our report further highlights the importance of paying attention to the serious complications of COVID-19 disease as well as its treatment of opportunistic infections.

To conclude, physicians should be mindful of the probability of secondary fungal infections in patients with COVID-19 who were managed by corticosteroids even in the absence of any comorbidities. Moreover, the importance of a multidisciplinary approach should be considered.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| CT | Computerized tomography |
| RT-PCR | Real-time reverse transcription-polymerase chain reaction |
| WBC | White blood cell counts |
| IV | Intravenous |
| Pt | Patient |
| MRI | Magnetic resonance imaging |
| mg | Milligram |
| BUN | Blood urea nitrogen |
| Rt | Right |
| Lt | Left |
| PNS | Paranasal sinuses |
| Fess | Functional endoscopic sinus surgery |
| COVID-19 | Coronavirus disease 2019 |
| WHO | World Health Organization |

**Data Availability**

All relevant data regarding this case report have been reported in the manuscript. Please contact the corresponding author for any further information.

**Ethical Approval**

The present study was approved by the Medical Ethics Committee of Shiraz University of Medical Sciences. The study's purpose was completely explained to the patient, and he was assured that his information would be kept confidential by the researchers.
Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written informed consent is available for review by the editor of this journal.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
ZM and MS conceived the idea for the manuscript. MRS contributed to reporting the radiological images. MJ A made a definitive diagnosis by pathology and took tissue photographs. MHZ, FM, and KN drafted the manuscript. AS, ZE, and HJM edited the manuscript. All authors read and approved the final manuscript. Zeinab Mehrabi is an Assistant Professor of Pathology, Shiraz University of Medical Sciences. Mohammad Reza Sasani is an Assistant Professor of Radiology, Shiraz University of Medical Sciences. Mohammad Javad Ashraf is an Associate Professor of Pathology, Shiraz University of Medical Sciences.

Acknowledgments
The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, and also the Center for Development of Clinical Research of Nemazee Hospital and Dr. Nasrin Shokrpour for editorial assistance.

References
[1] A. Skiada, C. Lass-Floerl, N. Klimko, A. Ibrahim, E. Roilides, and G. Petrikkos, “Challenges in the diagnosis and treatment of mucormycosis,” Medical Mycology, vol. 56, Supplement 1, pp. 93–101, 2018.
[2] F. Salahshour, M.-M. Mehrabinejad, M. Nassiri Toosi et al., “Clinical and chest CT features as a predictive tool for COVID-19 clinical progress: introducing a novel semi-quantitative scoring system,” European Radiology, vol. 31, no. 7, pp. 5178–5188, 2021.
[3] M. J. Zibaeeenzhad, M. Sayadi, H. Bzraftshan et al., “The prevalence of cardiovascular risk factors in fatal cases of COVID-19 in Fars Province, Iran,” International Cardiovascular Research Journal, vol. 15, no. 1, 2021.
[4] M. R. Hatamnejad, F. Fallah Tafiti, A. Abdi Ardekani, S. Sadeghi Boogar, and H. Bzraftshan, “Coronary thrombosis in a patient with COVID-19 who was on anticoagulant therapy,” International Cardiovascular Research Journal, vol. 15, no. 3, 2021.
[5] H. A. Fard, S. Mahmudi-Azer, S. Sefidbakht et al., “Evaluation of chest CT scan as a screening and diagnostic tool in trauma patients with coronavirus disease 2019 (COVID-19): a cross-sectional study,” Emergency Medicine International, vol. 2021, Article ID 4188178, 2021.
[6] H. Abdolrahimzadeh Fard, R. Borazjani, G. Sabetian et al., “Establishment of a novel triage system for SARS-CoV-2 among trauma victims in trauma centers with limited facili-
ties,” Trauma Surgery & Acute Care Open, vol. 6, no. 1, article e000726, 2021.
[7] S. Fujishima, “COVID-19: stay cool toward corticosteroids,” The Keio Journal of Medicine, vol. 69, no. 2, pp. 27–29, 2020.
[8] J.-W. Yang, L. Yang, R.-G. Luo, and J.-F. Xu, “Corticosteroid administration for viral pneumonia: COVID-19 and beyond,” Clinical Microbiology and Infection, vol. 26, no. 9, pp. 1171–1177, 2020.
[9] P. Mattos-Silva, N. S. Felix, P. L. Silva et al., “Pros and cons of corticosteroid therapy for COVID-19 patients,” Respiratory Physiology & Neurobiology, vol. 280, p. 103492, 2020.
[10] B. J. Langford, M. So, S. Rayhardhan et al., “Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis,” Clinical Microbiology and Infection, vol. 26, no. 12, pp. 1622–1629, 2020.
[11] X. Chen, B. Liao, L. Cheng et al., “The microbial coinfection in COVID-19,” Applied Microbiology and Biotechnology, vol. 104, no. 18, pp. 7777–7785, 2020.
[12] S. Mehta and A. Pandey, “Rhino-orbital mucormycosis associated with COVID-19,” Cureus, vol. 12, no. 9, article e10726, 2020.
[13] Z. Yang, J. Liu, Y. Zhou, X. Zhao, Q. Zhao, and J. Liu, “The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis,” The Journal of Infection, vol. 81, no. 1, pp. e13–e20, 2020.
[14] L. Zha, S. Li, L. Pan et al., “Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19),” The Medical Journal of Australia, vol. 212, no. 9, pp. 416–420, 2020.
[15] Y. Ma, H. Zeng, Z. Zhan et al., “Corticosteroid use in the treatment of COVID-19: a multicenter retrospective study in Hunan, China,” Frontiers in Pharmacology, vol. 11, pp. 1198, 2020.
[16] P. Badiee, Z. Jafarpour, A. Alborzi, P. Haddadi, M. Rasuli, and M. Kalani, “Orbital mucormycosis in an immunocompetent individual,” Iranian Journal of microbiology, vol. 4, no. 4, pp. 210–214, 2012.
[17] F. Lanternier, E. Dannaoui, G. Morizot et al., “A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007),” Clinical Infectious Diseases, vol. 54, Supplement 1, pp. S35–S43, 2012.
[18] A. D. Castrejón-Pérez, E. C. Welsh, I. Miranda, J. Ocampo-Candiani, and O. Welsh, “Cutaneous mucormycosis,” Anais Brasileiros de Dermatologia, vol. 92, no. 3, pp. 304–311, 2017.
[19] A. Werthman-Ehrenreich, “Mucormycosis with orbital compartment syndrome in a patient with COVID-19,” The American journal of Emergency Medicine, vol. 50735–6757, no. 20, pp. 30823–30826, 2020.
[20] Z. K. Mekonnen, D. C. Ashraf, T. Jankowski et al., “Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome,” Ophthalmic Plastic & Reconstructive Surgery, vol. 37, no. 2, pp. e40–e80, 2021.
[21] E. S. do Monte Junior, M. E. L. dos Santos, I. B. Ribeiro et al., “Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report,” Clinical Endoscopy, vol. 53, no. 6, pp. 746–749, 2020.
[22] D. Pasero, S. Sanna, C. Liperi et al., “A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis,” Infection, vol. 49, no. 5, pp. 1055–1060, 2021.
[23] V. Muthu, S. M. Rudramurthy, A. Chakrabarti, and R. Agarwal, “Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world,” Mycopathologia, pp. 1–16, 2021.

[24] S. M. Rudramurthy, M. Hoenigl, J. F. Meis et al., “ECMM/I-SHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries,” Mycoses, vol. 64, no. 9, pp. 1028–1037, 2021.

[25] A. Bhattacharyya, P. Sarma, D. J. Sharma et al., “Rhino-orbital-cerebral-mucormycosis in COVID-19: a systematic review,” Indian Journal of Pharmacology, vol. 53, no. 4, pp. 317–327, 2021.